USPTO Examiner HABTE KAHSAY - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19069098MACROCYCLIC DERIVATIVE AND USE THEREOFMarch 2025June 2025Allow301NoNo
19052553THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2025June 2025Allow410NoNo
18972557BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSDecember 2024April 2025Allow501NoNo
18934931THIAZOLE COMPOUNDS AND METHODS OF USE THEREOFNovember 2024February 2025Allow401NoNo
18884381AMIDO HETEROAROMATIC COMPOUNDSSeptember 2024March 2025Allow611NoNo
188826491,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOFSeptember 2024February 2025Allow501NoNo
18838246C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERAugust 2024April 2025Allow811NoNo
18800565IMIDAZOLO DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTSAugust 2024November 2024Allow311NoNo
18778527HETEROCYCLIC COMPOUNDS AND USES THEREOFJuly 2024October 2024Allow311NoNo
18775819FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOFJuly 2024May 2025Allow911NoNo
18764004CRYSTALLINE SALT FORMS OF KAPPA OPIOID RECEPTOR ANTAGONIST AND PRODUCTS AND METHODS RELATED THERETOJuly 2024August 2024Allow200NoNo
18724932PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTSJune 2024December 2024Allow601NoNo
18740233SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONSJune 2024May 2025Allow1101NoNo
18675780CRYSTALLINE SOLID FORMS OF A BET INHIBITORMay 2024July 2025Allow1310NoNo
18668025HETEROCYCLIC COMPOUNDS AND USES THEREOFMay 2024July 2024Allow200NoNo
18661650HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERSMay 2024September 2024Allow411NoNo
18641842PHEBOX LIGANDS AND METHODS OF MAKING SAMEApril 2024December 2024Allow800NoNo
18639255POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4April 2024June 2024Allow200NoNo
18635839HETEROCYCLIC COMPOUNDApril 2024March 2025Allow1110NoNo
18630109THERAPEUTIC COMPOUNDS AND METHODSApril 2024April 2025Allow1210NoNo
18623812BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOFApril 2024April 2025Allow1210NoNo
18612631FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOFMarch 2024December 2024Allow921NoNo
18600352NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOFMarch 2024June 2024Allow300NoNo
18600347NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOFMarch 2024November 2024Abandon801NoNo
18596024MULTICYCLIC COMPOUNDSMarch 2024May 2024Allow300NoNo
18584440INDAZOLE COMPOUNDS AS KINASE INHIBITORSFebruary 2024May 2024Allow311NoNo
18430456COMPOUNDS AND METHODS OF USEFebruary 2024September 2024Allow711NoNo
18430429COMPOUNDS AND METHODS OF USEFebruary 2024November 2024Allow1011NoNo
18417159PIPERIDINE DERIVATIVES AS METTL3 INHIBITORSJanuary 2024May 2024Allow401NoNo
18413744PYRIDO[3,4-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINES AS CK2 INHIBITORSJanuary 2024August 2024Allow711NoNo
18538309PRO DRUGS OF PDE10 COMPOUNDSDecember 2023September 2024Allow920NoNo
18534520COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITYDecember 2023March 2025Allow1510NoNo
18533515METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDSDecember 2023April 2025Abandon1610NoNo
18527398STRUCTURAL ANALOG OF CYCLOTHEONELLAZOLE A, AND SYNTHETIC METHOD THEREFOR AND APPLICATION METHOD THEREOFDecember 2023September 2024Allow1001NoNo
18526922FLUOROALKYL-OXADIAZOLES AND USES THEREOFDecember 2023March 2025Allow1511NoNo
18525253MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODSNovember 2023November 2024Allow1210NoNo
18512361MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOFNovember 2023April 2025Allow1720NoNo
18510883NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVENovember 2023July 2024Allow811NoNo
18507566LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOFNovember 2023May 2024Allow611YesNo
18504559INHIBITORS OF APOL1 AND METHODS OF USING SAMENovember 2023April 2025Allow1810NoNo
183876804,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(3-PYRIDYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
183859929-(2-HYDROXYPYRIDIN-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow401NoNo
18558337NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVEOctober 2023April 2025Allow1801NoNo
18558188PHENANTHROIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFOctober 2023July 2024Allow901NoNo
18496504ISOINDOLINONE COMPOUNDSOctober 2023March 2025Allow1610NoNo
183834482-[(1,3-BENZOXAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow401NoNo
18381016SYNTHESIS OF THIAZOLE DERIVATIVESOctober 2023March 2024Allow511NoNo
18379891N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZO[D][1,3]DIOXOLE-5 CARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow301NoNo
18486126N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZO[D][1,3]DIOXOLE-5-CARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow301NoNo
18484675Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerOctober 2023March 2025Abandon1710NoNo
18369069NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOFSeptember 2023May 2025Allow2011NoNo
18368244NMDA RECEPTOR MODULATORS AND USES THEREOFSeptember 2023March 2025Allow1811NoNo
18367517GLP-1 Receptor Agonist and Composition and Use ThereofSeptember 2023February 2024Allow501NoNo
18460464PYRIDAZINONE COMPOUNDS AND USES THEREOFSeptember 2023September 2024Allow1301NoNo
18460072METHOD FOR SYNTHESIZING (S)-NICOTINE AND INTERMEDIATE THEREOFSeptember 2023October 2023Allow200NoNo
182392791,3-BENZOTHIAZOL-2-YL-N'-[(PYRIDINE-3-CARBONYL)OXY]ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDAugust 2023January 2024Allow411NoNo
18237824PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONSAugust 2023February 2025Allow1810NoNo
18452278POLO LIKE KINASE 4 INHIBITORSAugust 2023January 2025Allow1710NoNo
18231628ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOFAugust 2023January 2025Abandon1710NoNo
18363195THERAPEUTIC COMPOUNDS AND METHODSAugust 2023January 2024Allow511NoNo
18362576KRAS MODULATORS AND USES THEREOFJuly 2023December 2023Allow411NoNo
18353718QUINOLINE cGAS ANTAGONIST COMPOUNDSJuly 2023June 2024Allow1131NoNo
18350452HETEROARYL INHIBITORS OF PDE4July 2023January 2025Allow1910NoNo
18349634ISOINDOLINONE COMPOUNDSJuly 2023September 2023Allow300NoNo
18259422INDAZOLE COMPOUNDS AS KINASE INHIBITORSJune 2023November 2024Allow1611NoNo
18335225SPIROCYCLIC COMPOUNDSJune 2023September 2023Allow300NoNo
18335480CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORSJune 2023August 2024Allow1400NoNo
18332897N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDESJune 2023August 2023Allow200NoNo
18206925NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORSJune 2023September 2024Allow1520NoNo
182041361H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINSMay 2023October 2024Allow1610NoNo
18325502TRIAZINE DERIVATIVES AND METHODS OF USE THEREOFMay 2023October 2024Allow1711NoNo
18202993SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASISMay 2023December 2024Allow1810NoNo
18322492COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITYMay 2023October 2023Allow401NoNo
18199899Process for the Stereoselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable TherefromMay 2023December 2024Allow1810NoNo
18315291THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOFMay 2023February 2025Allow2201NoNo
18144030COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOFMay 2023November 2024Allow1911NoNo
18310730PYRIDINONE MK2 INHIBITORS AND USES THEREOFMay 2023July 2024Allow1400NoNo
18250795HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERSApril 2023April 2025Allow2311NoNo
18308441POLO LIKE KINASE 4 INHIBITORSApril 2023July 2023Allow300NoNo
183074906-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORSApril 2023November 2024Allow1810NoNo
18306867SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERSApril 2023July 2024Allow1401NoNo
18298313C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORSApril 2023September 2024Allow1710NoNo
18131955SYNTHESIS OF THIAZOLE DERIVATIVESApril 2023September 2023Allow511NoNo
18128085AMINOCARBAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023September 2023Allow510YesNo
18126676BICYCLIC UREA KINASE INHIBITORS AND USES THEREOFMarch 2023March 2025Allow2421NoNo
18119742CARBAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023July 2023Allow510NoNo
18118280INDOLE-BASED CHALCONE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023June 2023Allow300NoNo
18178325SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORSMarch 2023June 2024Allow1510NoNo
18177732QUINOLINE cGAS ANTAGONIST COMPOUNDSMarch 2023November 2024Allow2131NoNo
18043508FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOFFebruary 2023December 2024Allow2111NoNo
18175349HETEROCYCLIC COMPOUNDS AND USES THEREOFFebruary 2023June 2025Allow2711NoNo
18113859GLP-1R AGONISTS AND USES THEREOFFebruary 2023April 2025Abandon2601NoNo
18169496SMALL MOLECULE ACTIVATORS OF TIE-2February 2023August 2024Allow1810NoNo
18169785NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOFFebruary 2023October 2023Allow811NoNo
18167411PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASESFebruary 2023March 2025Abandon2521NoNo
18164185BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORSFebruary 2023August 2024Allow1810NoNo
18101511PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2January 2023June 2023Allow401NoNo
181569871,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 InhibitorsJanuary 2023February 2024Allow1301NoNo
18097782CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2023November 2024Allow2210NoNo
18096712[6,6] FUSED BICYCLIC HDAC8 INHIBITORSJanuary 2023June 2025Abandon2911NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HABTE, KAHSAY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
3
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.2%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
47
Allowed After Appeal Filing
21
(44.7%)
Not Allowed After Appeal Filing
26
(55.3%)
Filing Benefit Percentile
71.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 44.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner HABTE, KAHSAY - Prosecution Strategy Guide

Executive Summary

Examiner HABTE, KAHSAY works in Art Unit 1624 and has examined 2,611 patent applications in our dataset. With an allowance rate of 82.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 18 months.

Allowance Patterns

Examiner HABTE, KAHSAY's allowance rate of 82.5% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by HABTE, KAHSAY receive 1.08 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HABTE, KAHSAY is 18 months. This places the examiner in the 93% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +15.1% benefit to allowance rate for applications examined by HABTE, KAHSAY. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 40.7% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 69.2% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 166.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 91% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 91.9% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 85.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 44.1% are granted (fully or in part). This grant rate is in the 48% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 11.9% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 23.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.